Interventional radiology for post-transplant anastomotic complications

Toshiya Shibata¹,²

¹Department of Radiological Technology, Faculty of Medical Science, Kyoto College of Medical Science, Kyoto 622-0041, Japan.
²Department of Radiology, Kyoto University Graduate School of Medicine, Kyoto 606-8507, Japan.

Correspondence to: Dr. Toshiya Shibata, Department of Radiological Technology, Faculty of Medical Science, Kyoto College of Medical Science, 1-3 Imakita, Oyama-higashi, Sonobe, Nantan, Kyoto, 622-0041, Japan. E-mail: shibata@kyoto-msc.jp

How to cite this article: Shibata T. Interventional radiology for post-transplant anastomotic complications. Hepatoma Res 2017;3:221-7.

ABSTRACT

The effectiveness of percutaneous interventional radiology for anastomotic stricture in hepatic vein, portal vein, and biliary tract after living donor liver transplantation (LDLT) is described. As a number of patients with LDLT are infants < 10-year-old in the study, the first treatment option was balloon dilatation, not primary stenting. However, stent placement was performed in patients with recurrent, repeated stenosis.

Key words:
Interventional radiology,
living donor liver transplantation,
balloon dilatation,
stent placement

INTRODUCTION

Liver transplantation is an established treatment for end-stage liver disease[1]. The recent advances in surgical techniques and immunosuppression have led to improvements of post-transplant outcomes but various complications including bleeding, infections, rejection, vascular complications at the anastomotic site, and biliary complication will occur after liver transplantations[2,3]. Although deceased donor liver transplantation is considered a standard procedure, living donor liver transplantation (LDLT) has been widely performed owing to the shortage of donors[4]. LDLT is technically demanding because of the use of short vascular pedicles, which are more likely to cause postoperative vascular complications, such as hepatic venous outflow obstruction (HVOO) at the anastomotic site and anastomotic portal vein stenosis (PVS)[5-8]. Moreover, biliary complications remain common after LDLT, and some studies suggested that biliary stricture at the anastomotic site occurs more frequently in post-LDLT patients than in deceased liver transplantation. This is because of the small diameter of the anastomotic portion of the bile duct, anatomical diversity of the bile ducts or the complicated nature of the surgical procedure[9,10].

In this study, the effectiveness of interventional radiology (IR) for anastomotic complications after LDLT mainly in pediatric patients was described.

This is an open access article licensed under the terms of Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original author is credited and the new creations are licensed under the identical terms.

For reprints contact: service@oaepublish.com
IR FOR HVOO

Vascular complications after liver transplantation include occlusion/stenosis at the site of anastomosis of hepatic artery, portal vein and hepatic vein. Although HVOO is an uncommon complication after liver transplantation, it is still an important cause of graft failures after liver transplantation.[2] The incidence of HVOO after orthotopic liver transplantation is reported to be about 1% and that after LDLT is reported to be about 2-4%.[11,12] This is because an anastomotic orifice is small and the grafts grow in LDLT. The causes of HVOO were stretching, twist and compression of hepatic vein with graft growing and adhesion change at anastomotic site.[13]

HVOO are suspected with the findings of intractable ascites, abnormal venous flow patterns at Doppler ultrasonography (US), histologic findings suggesting venous congestion, or deterioration of liver function not otherwise explained. Doppler US is a useful modality for diagnosing HVOO whose findings is disappearance of pulsatile hepatic venous flow or flatness of the hepatic venous wave.

Percutaneous balloon dilatation is a safe and effective method of treating HVOO. In our study balloon dilatation is performed for patients with initial HVOO after LDLT, and expandable metallic stent placement is tried in patients with repeated HVOO after the balloon dilatation. This strategy is based on three our concepts. First, routine primary stenting may result in unnecessary placement of an expandable metallic stent. Second, long-term patency for metallic stent for decades is unknown in pediatric patients. Because infant and young patients grow, it is unknown whether their growth can match to the unchanged size of implanted expandable metallic stent. Third, implanted expandable metallic stent may disturb re-transplantation. At re-transplantation, the presence of expandable metallic stent in the wall of the suprahepatic inferior vena cava might be technically a challenge for surgeons.

Procedures

The approach to the hepatic vein is made through transjugular or transhepatic method. After passage of the catheter through the stenotic segment of the hepatic vein, venography and manometry; measurement of venous pressure of proximal and distal sides of the stenosis and the pressure gradient across the stricture is performed. Patients with a pressure gradient of more than 3 mmHg are considered to have significant outflow obstruction and are candidates for balloon dilatation.

Balloon dilatation [Figure 1] is performed following venography with a 7.0-Fr percutaneous transluminal angioplasty catheter with a balloon diameter of 6-12 mm. The balloon is inflated three times for 60 s with an atmospheric pressure of 10 atm. The diameter of the balloon is the same as the vein on the mesenteric side of the stenosis. The balloon is routinely inflated 3 times for 60 s with an atmospheric pressure of 10 atm. In patients showing recurrent HVOO, the stent placement [Figure 2] is performed. We used a self-expanding metallic stent with a diameter 20-30% larger than that of the hepatic vein.

Results

In our reported study.[14] the rates of technical success, primary patency and primary-assisted patency were evaluated. Technical success is defined as success in interventional procedures. Primary patency is defined as the interval between the initial balloon angioplasty and recurrent HVOO necessitating percutaneous intervention. Primary-assisted patency is defined as patency following the initial angioplasty until repeated percutaneous intervention therapy is discontinued.

We performed IR for 48 patients with HVOO after LDLT whose follow-up periods ranged from 1 to 182 months (median, 51.5 months). Technical success was achieved in 92 of 93 sessions (99%) and in 47 of 48 patients.
The primary and primary assisted patency at 1, 3, 5, 10 years after the initial privacy threshold analysis (PTA) were 64%, 57%, 57%, 52% and 98%, 95%, 95%, and 95% respectively.

IR FOR PVS

The rate of PV complications after deceased donor liver transplantation has been reported to be < 3%[7]. However, in patients with reduced-size liver transplantation or LDLT, the rate of PV complication can be higher (9-14%) than in patients with conventional deceased donor liver transplantation[7,19]. PV complications are divided mainly into anastomotic PVS and portal vein thrombosis (PVT)[16]. Anastomotic PVS can lead to graft failure if not properly treated. The treatment options for PVS after liver transplantation are surgical treatment and percutaneous interventions, including percutaneous balloon dilatation and stent placement. However, surgical treatment of these complications has been limited owing to technical difficulties or invasiveness. Currently, the surgical treatment of PVS after liver transplantation has been replaced by percutaneous balloon dilatation and stent placement, because of lower invasiveness and greater effectiveness.

PVS was clinically suspected with the following findings: (1) clinical symptoms of portal hypertension, such as ascites, splenomegaly, gastrointestinal tract bleeding from varices, and thrombocytopenia; and (2) US findings, including greater than 50% stenosis (the diameter of stenosis/the diameter of a main PV on the mesenteric side) or no flow in the PV; or the presence of an acceleration of flow at the stenosis or a post-stenotic jet flow or minimal flow in the intrahepatic PV on Doppler US. Our inclusion criteria for PVS were: (1) greater than 50% stenosis (the diameter of the stenosis/the diameter of a PV on the distal side); or (2) > 5 mmHg pressure gradient across the stenosis between the proximal and distal PV.

Procedures

The approach to the intrahepatic PV is transhepatic at the first session of percutaneous intervention. Balloon dilatation [Figure 3] is performed following portography with a 7.0-Fr percutaneous transluminal angioplasty catheter with a balloon diameter of 6-12 mm. The balloon...
is inflated three times for 60 s with an atmospheric pressure of 10 atm. The diameter of the balloon is the same as the vein on the mesenteric side of the stenosis. The balloon is routinely inflated three times for 60 s with an atmospheric pressure of 10 atm. Stent placement [Figure 4] is performed in patients who developed recurrent PVS. We used a self-expanding metallic stent with a diameter 20-30% larger than that of the PV proximal to the stenosis and with sufficient length to cover the stricture. In patients where the percutaneous transhepatic approach to the PV is unsuccessful, or where placing a metallic stent with the percutaneous transhepatic approach might be technically difficult owing to a severely curved PV, a transileocecal approach is chosen following laparotomy.

**Results**

In our reported study\(^{[17]}\), the rates of technical success, primary patency and primary-assisted patency were evaluated. Technical success is defined as success in interventional procedures. Primary patency is defined as the interval between the initial balloon angioplasty and recurrent PVS necessitating percutaneous intervention. Primary-assisted patency is defined as patency following the initial angioplasty until repeated percutaneous intervention therapy is discontinued.

We performed IR for the 43 patients with PVS after LDLT, whose follow-up periods ranged from 5 to 169 months (mean, 119 months). Technical success was achieved in 65 of 66 sessions (98%) and in 42 of 43 patients (98%). The primary and primary assisted patency at 1, 3, 5, 10 years after the initial PTA were 83%, 78%, 76%, and 70%, respectively, and 100%, 100%, 100%, and 96%, respectively [Figure 5].

**IR FOR ANASTOMOTIC BILIARY STENOSIS**

Anastomotic biliary stricture is the most common biliary complication. Some studies have suggested that biliary stricture occurs more frequently in post-LDLT patients than in deceased liver transplantation because of the small diameter of the anastomotic portion of the bile duct, anatomical diversity of the bile ducts, or the complicated nature of the surgical procedure\(^{[9,10,18]}\). There are two strategies for treating anastomotic strictures: via the endoscopic retrograde approach\(^{[19]}\) or the percutaneous transhepatic approach\(^{[20]}\). The endoscopic retrograde approach is feasible for post-transplant patients with a duct-to-duct anastomosis, and endoscopic stent placement has been reported to be effective for biliary strictures in post-transplant patients\(^{[21]}\). Because the most common disease in pediatric patients with LDLT has been biliary atresia, most of them have undergone Kasai’s surgery and Roux-en-Y hepaticojejunostomy (RYHJ). Thus, percutaneous transhepatic biliary drainage (PTBD) is believed to be a first-line treatment for biliary strictures in pediatric patients who underwent LDLT with RYHJ.

An anastomotic biliary stricture is suspected based on laboratory, US, cholescintigraphic findings, and liver biopsy results. Liver function tests show increases in total bilirubin, direct bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), r-glutamyl transpeptidase (r-GTP), and/or alkaline phosphatase (ALP). US findings that suggest anastomotic stricture are dilatation of intrahepatic bile ducts that appeared during the follow-up. Cholescintigraphy shows delayed visualization of the bowel (> 10 min after injection of the radiotracers (99mTc-N-pyridoxyl-5-methyltryptophan). Liver biopsy reveals cholestasis.

**Procedures**

Access to the biliary duct was made under US guidance. After puncture of a biliary duct with a 21-gauge needle under US guidance and opacifying the biliary duct (percutaneous transhepatic cholangiography), PTBD is performed using a 0.018-inch guidewire and a 5-Fr catheter [Figure 6]. Then, passage through the anastomotic biliary stricture is attempted with a 0.035-inch hydrophilic guidewire and a 5-Fr catheter. After successful passage of the catheter and exchange of a 7-Fr interventional sheath introducer [Figure 6], dilatation was performed with a balloon catheter (diameter; 4-10 mm). The diameter of the balloon was matched to the diameter of the intrahepatic bile duct on the hepatic side of stricture. The balloon was placed across the stricture and inflated for 180 s with
Shibata

Living donor liver transplantation anastomotic stenosis interventional radiology balloon dilatation

an atmospheric pressure of 10 atm. After balloon dilatation, cholangiography was repeated to evaluate the effectiveness. Then, an 8.5-Fr internal-external drainage tube (Pig-tail catheter, Cook; IN, USA) was placed, covering the Roux-Y jejunum and intrahepatic bile ducts across the anastomotic stricture.

Serial exchanges for a larger 14-Fr or 16-Fr drainage tube with or without balloon dilations were routinely performed at 1- to 6-week intervals. At a follow-up session, cholangiography was performed to evaluate the persistence of stricture. If the stricture had widened and the laboratory data had resolved, the tube was removed.

Results

In our reported study\cite{22}, clinical success, tube independent rate, and patency rate were evaluated. Clinical success is defined as resolution or marked improvement of clinical symptoms including fever, and improvement of laboratory findings, including the serum levels of AST, ALT, total bilirubin, direct bilirubin, r-GTP, and ALP. Tube independent rate is defined as the rate at which the patient can undergo tube removal after symptoms are diminished and laboratory findings have improved. Patency rate is estimated by the Kaplan-Meier analysis. Primary patency is defined as the interval between placement of an internal drainage tube and appearance of a recurrent biliary stricture necessitating percutaneous biliary interventions. Primary-assisted patency is defined as the interval between placement of an internal drainage tube and when treatment with repeated percutaneous interventions is discontinued.

We performed IR for the 52 patients with anastomotic biliary stenosis after LDLT, whose follow-up periods

\[\text{Figure 5: Kaplan-Meier curve showing primary- and primary-assisted patency rates. Solid and dotted lines indicate primary patency and primary-assisted patency, respectively. Vertical lines on both lines indicate censored observations. At 1, 3, 5, and 10 years after the first balloon angioplasty the primary patency rates were 80%, 76%, 73%, and 67%, respectively, and the primary-assisted patency rates were 100%, 100%, 100%, and 96% respectively.}\]

\[\text{Figure 6: A 2-year-old boy who had undergone LDLT 20 months ago was suspected of having a biliary anastomotic stricture. (A) PTC showing an anastomotic stricture; (B) fluoroscopic view during balloon dilatation. Balloon dilatation was performed at 10 atm for 3 min using a 6-mm-diameter balloon catheter; (C) fluoroscopic view shows an 8.5-Fr, internal-external drainage tube placed across the anastomotic stricture. After serial exchange with a larger diameter catheter (16-Fr), the drainage tube was removed. No recurrent stricture was noted for 117 months after the biliary interventions. LDLT: living donor liver transplantation; PTC: percutaneous transhepatic cholangiography.}\]

\[\text{Figure 7: Kaplan-Meier curve showing primary- and primary-assisted patency rates. Solid and dotted lines indicate primary patency and primary-assisted patency, respectively. Vertical lines on both lines indicate censored observations. The primary patency rates at 1, 3, 5, and 10 years after the initial drainage tube placement were 75%, 70%, 70%, and 68%, respectively. The primary-assisted patency rates at 1, 3, 5, and 10 years after the initial drainage tube placement were 94%, 92%, 88%, 88%, respectively.}\]
ranged from 5 to 206 months (median, 100 months). Clinical success was noted in 43 of 52 patients (83%). Removal of the drainage tube was achieved in 49 of 52 patients (94%). Of the three patients having a drainage tube, two underwent surgical reanastomosis, and one had a drainage tube implanted subcutaneously. The primary patency rates at 1, 3, 5, and 10 years after the initial drainage tube placement were 75%, 70%, 70%, and 68%, respectively. The primary-assisted patency rates at 1, 3, 5, and 10 years after the initial drainage tube placement were 94%, 92%, 88%, and 88%, respectively [Figure 7].

**CONCLUSION**

In conclusion, percutaneous IR is a minimally invasive, effective treatment for HVOO, PVS, and anastomotic biliary stenosis after LDLT.

**DECLARATIONS**

**Authors’ contributions**
The author contributed solely to this paper.

**Financial support and sponsorship**
None.

**Conflicts of interest**
There are no conflicts of interest.

**Patient consent**
Not applicable.

**Ethics approval**
This review paper is waived for ethics approval.

**REFERENCES**
